9Pancreatic cancer in patients with chronic pancreatitis: Incidenceand risk factorsS.T. Barbu*, I. Lupu***IVth Surgical Clinic, **Social Medicine Unit, University of Medicine and Pharmacy "IuliuHatieganu" Cluj-Napoca, RomaniaIntroduction: Patients with chronic pancreatitis (CP) have an increased risk forpancreatic cancer (PCc), a malignancy with late diagnosis and fatal outcome.Purpose: To assess frequency and risk factors for PCc in our patients withnon-hereditary CP.Methods: We performed a retrospective record analysis and a subsequent prospectivefollow-up of 136 patients operated in our clinic between 1993 and 2002 fornon-hereditary CP. At laparotomy, 3 males (38, 51 and 56 years old) were found tohave ductal adenocarcinoma developed on CP (final tissue diagnosis). Standardizedincidence ratio (SIR) was calculated for 2121 patient years of follow-up. To find riskfactors for PCc, we applied a Pearson correlation test and a nonlinear estimation for thefollowing factors: age, sex, occupation, alcohol intake (dose, years of drinking), cigarettesmoking (number of cigarettes, years of smoking), coffee consumption, fat diet, CPduration, number of CP complications, presence of diabetes and calcifications. Forsignificant associations, relative risk (RR) was calculated.Results: SIR of PCc was 12.76. We found that male sex, cigarette smoking, fat diet, CPduration, alcoholic etiology and number of complications are strong risk factors for PC(p < 0.005). Factors association leads to higher RR.Discussion/Conclusion: CP is an independent risk factor for development of PCc. Wedescribe a new risk factor for PCc in patients with CP: number of previous CPcomplications requiring operation, which possibly accelerates dysplasia. Presence ofrisk factors in CP patients suggests the need for closer follow-up and an aggressivesurgical approach if malignancy is suspected.
10High expression of agrin in hepatocellular and cholangiocellularcarcinomaBatmunkh E. 1 , Lodi Cs. 1 , Holczbauer A. 1 , Szabo E. 1 , Tatrai P. 2 , Paska Cs. 1 Kiss A. 1 ,Kupcsulik P. 3 , Ilona Kovalszky 2 , Schaff Zs. 11 2nd Dept. of Pathology, Semmelweis University, Budapest, Hungary, 2 1st Dept. ofPathology and Experimental Cancer Research, Semmelweis University, Budapest,Hungary, 3 1st Dept. of Surgery, Semmelweis University, Budapest, HungaryIntroduction: The synthesis of proteoglycans, as one of the major component of ECM,was shown to be changed during neoplastic transformation both in tumors andsurrounding tissues. Agrin, being a heparan sulfate proteoglycan constituent of thebasement membrane, was implicated in the regulation of cell growth, differentiation,adhesion and motility.Our goal, therefore, was to investigate mRNA and protein expression of agrin inhepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC) to analyse itsinvolvement in tumorigenesis.Methods: Twenty-one cases of CCC and HCC, respectively, and 7 normal liver sampleswere studied. mRNA expression was evaluated by real-time PCR using relativequantification and beta-actin as reference gene. Protein expression was detected byimmunohistochemistry in tissue sections and by Western blot analysis in tissuehomogenates.Results: Immunohistochemistry showed mild positivity around the bile ducts and theblood vessels within the portal area in normal liver, however, no expression within thehepatic lobules was found. HCC presented intense expression along the neovascularbasement membrane. In CCC well differentiated areas showed strong agrin expressionin tumor specific basement membrane, while in less differentiated areas and atinfiltration sites the staining was fragmented, decreased or even absence. Western blotanalysis and real-time PCR confirmed the increased expression of agrin in HCCs andCCCs compared with normal and surrounding nontumorous liver.Discussion/Conclusion: Agrin may play an important role in neoangiogenesis inhuman HCCs, as part of the newly formed vasculature. In CCCs, however, agrin mightbe involved in tumor progression.The project was supported by grants: Bio14/2001, NKFP-1/0023/2002, ETT- 228/2001,ETT-077/2003, OTKA-T037838
- Page 1 and 2:
BERLINAbstractsPoster AbstractsGAST
- Page 3 and 4:
CONTENTSpageCholelithiasis and bili
- Page 5 and 6:
Session Liver IDiagnosis and survei
- Page 7 and 8:
Poster Abstracts1. Autoimmune pancr
- Page 9 and 10:
24. Liver vascular index in NASH, c
- Page 11 and 12:
47. Expression of claudins in human
- Page 13 and 14:
67. Prevalence and association with
- Page 15 and 16:
90. Ursofalk ® in cholestatic live
- Page 17 and 18:
112. Agrin accumulates in the liver
- Page 19:
Molecular mechanisms controlling bi
- Page 22 and 23:
Etiology and pathogenesis of biliar
- Page 25 and 26:
Special Lecture IFuture development
- Page 27 and 28:
Pancreatic carcinoma
- Page 29 and 30:
3. One pancreatic cancer case with
- Page 31 and 32: However, the Melanoma Genetics Cons
- Page 33 and 34: the pancreas encouraging duodenum p
- Page 35 and 36: Pancreatic cancer: Surgery, palliat
- Page 37 and 38: Special Lecture IIIDevelopment comp
- Page 39 and 40: Special Lecture IVHow does pancreat
- Page 41 and 42: Session Liver IDiagnosis and survei
- Page 43 and 44: Imaging modalitiesProf. Riccardo Le
- Page 45 and 46: Session Liver IIMetabolic liver dis
- Page 47 and 48: The role of insulin resistance and
- Page 49 and 50: other adipocyte-derived factors, in
- Page 51 and 52: Hereditary hemochromatosis: The gen
- Page 53 and 54: Wilson disease: The impact of molec
- Page 55 and 56: Immune pathogenesis of hepatitis B
- Page 57 and 58: However, neither WHV DNA nor WHsAg
- Page 59 and 60: The well established antiviral ther
- Page 61 and 62: Genomics of hepatocellular carcinom
- Page 63 and 64: A prospective study of more than 22
- Page 65 and 66: treatment approach with HDACi toget
- Page 67 and 68: statistically significant differenc
- Page 69 and 70: Prof. Dr. H. FriessAllgemein-/Visze
- Page 71 and 72: Prof. Dr. W.E. SchmidtInnere Medizi
- Page 73 and 74: Autoimmune pancreatitis: An underdi
- Page 75 and 76: Non-invasive parameters for predict
- Page 77 and 78: Table 1Agegroups1986-1991m-w1992-19
- Page 79 and 80: NTCP-mediated bile acid transport i
- Page 81: 8The use of Ursofalk ® in patients
- Page 85 and 86: 12Chronic liver diseases associated
- Page 87 and 88: 14Determination of hepatitis Delta
- Page 89 and 90: 16Different expressions of claudins
- Page 91 and 92: For most of the morphological, hist
- Page 93 and 94: 19Clinical and diagnostic value of
- Page 95 and 96: The impact of steatosis in fibrosis
- Page 97 and 98: 23Unusual association between liver
- Page 99 and 100: 25Effect of molsidomine and sin-1 o
- Page 101 and 102: 27Concentration of antioxidative vi
- Page 103 and 104: 29An assessment of cardiovascular m
- Page 105 and 106: Conclusions:1. Hepatic stellate cel
- Page 107 and 108: 32Heme oxygenase-1 over-expression
- Page 109 and 110: 34Autoimmune processes and alpha-in
- Page 111 and 112: 36Therapy in non-alcoholic steatohe
- Page 113 and 114: 38A case of hepatocellular carcinom
- Page 115 and 116: 40Antigen-presenting cells in small
- Page 117 and 118: 42Spatial complexity analysis of th
- Page 119 and 120: Endocrine cells in the large bile d
- Page 121 and 122: 46Clinical features associated with
- Page 123 and 124: 48Effect of losartan on early liver
- Page 125: 50Assessment of histological featur
- Page 128 and 129: 53Non-alcoholic fatty liver disease
- Page 130 and 131: 55Helicobacter pylori infection and
- Page 132 and 133:
57Mild to moderate autonomic dysfun
- Page 134 and 135:
58Level of some proinflammatory cyt
- Page 136 and 137:
60Port-site metastasis after laparo
- Page 138 and 139:
62The influence of active prophylax
- Page 140 and 141:
63Progressive familiar intrahepatic
- Page 142 and 143:
65The survival rate among the Slova
- Page 144 and 145:
66ILEI, a novel key component and r
- Page 146 and 147:
68Clinical and pathological signifi
- Page 148 and 149:
70High expression of claudin-7 duri
- Page 150 and 151:
72Microhemorrheological disturbance
- Page 152 and 153:
74High level of vitamin C in rat li
- Page 154 and 155:
76Epidemiological analysis of HBV,
- Page 156 and 157:
78Evaluation of Ursofalk ® 's effe
- Page 158 and 159:
80Is the corticotherapy of malignan
- Page 160 and 161:
82Transdifferentiation of hepatocyt
- Page 162 and 163:
84The study of risk groups for chol
- Page 164 and 165:
86Thrombocytosis as a prognostic fa
- Page 166 and 167:
88Assessment of Helicobacter genus
- Page 168 and 169:
90Ursofalk ® in cholestatic liver
- Page 170 and 171:
92Activated hepatic stellate cells
- Page 172 and 173:
94What is the actual prevalence of
- Page 174 and 175:
96Hepatectomy for huge HCCJing-An R
- Page 176 and 177:
98Increased expression of geranylge
- Page 178 and 179:
100Helicobacter pylori eradication
- Page 180 and 181:
102Treatment of pediatric metabolic
- Page 182 and 183:
103A 5-years single center experien
- Page 184 and 185:
104Tissue factor expression in inte
- Page 186 and 187:
106Expression of matrilin-2 in live
- Page 188 and 189:
108The significance of immunohistoc
- Page 190 and 191:
110Hepatocellular carcinoma in pati
- Page 192 and 193:
112Agrin accumulates in the liver d
- Page 194 and 195:
114Prophylaxis of encephalopathy in
- Page 196 and 197:
115Metadoxine modifies both apoptot
- Page 198 and 199:
117Expression of the xenobiotic- an
- Page 200 and 201:
Discussion/Conclusion: Compared wit
- Page 202 and 203:
120Functional and morphological inj
- Page 204 and 205:
Author Index to Poster Abstracts(Na
- Page 206 and 207:
Guizzetti, M. 102Gulubova, M.V. 44,
- Page 208 and 209:
Pascu, O. 94Páska, C. 10, 47, 106P